🔎 Trials Near Me

Akèy › Myelom Miltip › Wisconsin

Etid klinik pou Myelom Miltip nan Wisconsin

28 etid pou Myelom Miltip ap chèche patisipan nan sit nan Wisconsin.

Vil nan Wisconsin

Tèks ofisyèl etid la (Anglè)

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

  • Mayo Clinic Health System-Eau Claire Clinic, Eau Claire
  • Mayo Clinic Health System-Franciscan Healthcare, La Crosse
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06630104

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  • Research Site, Madison
  • Research Site, Milwaukee
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07391657

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

  • University of Wisconsin Carbone Cancer Center, Madison
  • Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT04973605

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  • Medical College Of Wisconsin, Milwaukee
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07258511

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

  • Froedtert Memorial, Milwaukee
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05201781

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

  • The Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07116616

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • Aurora Cancer Care - Burlington, Burlington
  • Aurora Health Care - Germantown Health Center, Germantown
  • Aurora Cancer Care - Grafton, Grafton
  • ak 13 plis
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06297226

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

  • University of Wisconsin, Madison
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT07479979

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

  • Research Site, Milwaukee
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07681596

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
  • University of Wisconsin Carbone Cancer Center-University Hospital, Madison
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06152575

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • ThedaCare Regional Cancer Center, Appleton
  • Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton, Appleton
  • Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield, Brookfield
  • ak 47 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04566328

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

  • Gundersen Lutheran, La Crosse
Ap rekriteFaz 3
Laj 18 a 79 · Tout sèks · Mizajou Aug 17, 2026 · NCT07285239

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  • Research Site, Milwaukee
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05850234

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

  • Froedtert & the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1
Laj 18 a 80 · Tout sèks · Mizajou Aug 10, 2026 · NCT05976555

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  • University of Wisconsin - Carbone Cancer Center, Madison
  • MCW-Clinical Cancer Center at Froedtert Hospital Campus, Milwaukee
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07284758

Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma

  • Medical College of Wisconsin, Milwaukee
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07236502

Integrated Cancer Repository for Cancer Research

  • Bellin Memorial Hospital, Green Bay
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • Langlade Hospital and Cancer Center, Antigo
  • ThedaCare Regional Cancer Center, Appleton
  • Duluth Clinic Ashland, Ashland
  • ak 22 plis
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Jun 10, 2026 · NCT05561387

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  • St Vincent HSHS (Green Bay Oncology), Green Bay
  • University of Wisconsin Hospital and Clinics, Madison
  • Froedtert Memorial Lutheran Hospital, Milwaukee
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT05243797

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

  • University of Wisconsin Clinical Science Center, Madison
  • Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 2
Laj 19 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT06974786

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

  • Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 1, 2026 · NCT05862012

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency

  • Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jan 28, 2026 · NCT04240054

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

  • Froedtert & the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jan 5, 2026 · NCT07093554

Long-term Follow-up Study of Patients Receiving CAR-T Cells

  • Froedtert Hospital & Medical College of Wisconsin, Milwaukee
Ap rekriteEtid obsèvasyon
Laj 18 a 80 · Tout sèks · Mizajou Nov 10, 2025 · NCT03375619

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

  • Froedtert and the Medical College of Wisconsin, Milwaukee
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2025 · NCT05722418

Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.